{"id":12671,"date":"2023-04-18T09:00:00","date_gmt":"2023-04-18T07:00:00","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=12671"},"modified":"2026-03-03T10:45:18","modified_gmt":"2026-03-03T09:45:18","slug":"3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/","title":{"rendered":"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) &#8211; Vice Chair Innovation Hub Committee"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\" id=\"h-quelles-sont-les-forces-et-les-chances-de-la-suisse-en-tant-que-place-de-recherche-et-d-innovation\"><strong><u>Quelles sont les forces et les chances de la Suisse en tant que place de recherche et d\u2019innovation?<\/u><\/strong><\/h2>\n\n\n\n<p>La Suisse a une longue tradition de performances de pointe dans l\u2019industrie pharmaceutique, avec de grands groupes internationaux comme Novartis, Roche et Nestl\u00e9, ainsi que de nombreuses entreprises de biotechnologie et de g\u00e9nie m\u00e9dical. Une autre grande force du pays sont les comp\u00e9tences consid\u00e9rables dans le domaine de la m\u00e9decine de pr\u00e9cision, du g\u00e9nie m\u00e9dical et de l\u2019engagement pour la fabrication de m\u00e9dicaments de haute qualit\u00e9. Par ailleurs, les hautes \u00e9coles suisses sont connues pour former du personnel scientifique et technique de pointe. L\u2019ETH, l\u2019EPFL et l\u2019Universit\u00e9 de Saint-Gall ne sont que quelques exemples de hautes \u00e9coles suisses du plus haut niveau qui assurent la rel\u00e8ve permanente de talents hautement qualifi\u00e9s.<\/p>\n\n\n\n<p>La position g\u00e9ographique unique de la Suisse est aussi une chance pour la recherche et l\u2019innovation: sa place au c\u0153ur de l\u2019Europe permet un acc\u00e8s rapide \u00e0 l\u2019Union europ\u00e9enne et \u00e0 d\u2019autres pays. La stabilit\u00e9 politique et l\u2019efficience de l\u2019infrastructure sont d\u2019autres atouts pour les entreprises de l\u2019industrie pharmaceutique.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><u>O\u00f9 voyez-vous les d\u00e9fis et probl\u00e8mes les plus urgents pour la place suisse?<\/u><\/strong><\/h2>\n\n\n\n<p>En d\u00e9pit de ses nombreuses forces, la Suisse est aussi confront\u00e9e \u00e0 divers d\u00e9fis et probl\u00e8mes en tant que place de recherche et d\u2019innovation. L\u2019un des plus urgents est la n\u00e9cessit\u00e9 d\u2019attirer et garder des talents. En raison du co\u00fbt de la vie \u00e9lev\u00e9 et de la politique d\u2019immigration stricte de la Suisse, il est difficile d\u2019attirer les meilleurs talents du monde entier.<\/p>\n\n\n\n<p>Un autre d\u00e9fi est la lourdeur administrative qui p\u00e8se sur la recherche clinique et l\u2019acc\u00e8s aux m\u00e9dicaments. L\u2019environnement r\u00e9glementaire complexe de la Suisse peut poser probl\u00e8me aux entreprises, de sorte que certaines vont d\u00e9localiser leurs activit\u00e9s dans d\u2019autres pays. De m\u00eame, la transformation num\u00e9rique et l\u2019acc\u00e8s aux donn\u00e9es de sant\u00e9 sont des sujets importants auxquels il faut s\u2019attacher pour rester comp\u00e9titifs.<\/p>\n\n\n\n<p>Enfin, les probl\u00e8mes actuels dans les relations de la Suisse avec l\u2019Europe sont un d\u00e9fi de taille. L\u2019incertitude caus\u00e9e par le Brexit et les n\u00e9gociations sur un nouvel accord institutionnel avec l\u2019UE pourraient porter atteinte \u00e0 l\u2019attractivit\u00e9 de la Suisse en tant que place pharmaceutique.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong><u>Que faut-il faire pour que la place pharmaceutique suisse reste attrayante \u00e0 l\u2019avenir et comment avez-vous l\u2019intention de vous engager personnellement dans ce domaine en tant que vice-pr\u00e9sident de l\u2019Innovation Hub Committee?<\/u><\/strong><\/h2>\n\n\n\n<p>Pour que la Suisse reste \u00e0 l\u2019avenir une place pharmaceutique attrayante, il faut continuer \u00e0 se concentrer sur l\u2019innovation et la recherche. Cela peut avoir lieu en encourageant des relations solides entre l\u2019industrie pharmaceutique, les institutions universitaires et les organismes publics.<\/p>\n\n\n\n<p>Une autre \u00e9tape importante est la mise en place d\u2019une future plaque tournante de donn\u00e9es de sant\u00e9 en Suisse. Cela permettrait d\u2019am\u00e9liorer l\u2019int\u00e9gration et l\u2019acc\u00e8s aux donn\u00e9es de sant\u00e9, et donc au final les r\u00e9sultats pour les patients. Par ailleurs, il faut continuer \u00e0 se concentrer sur des investissements durables dans l\u2019industrie pharmaceutique suisse de mani\u00e8re \u00e0 assurer le succ\u00e8s \u00e0 long terme.<\/p>\n\n\n\n<p>En tant que vice-pr\u00e9sident de l\u2019IHC, je souhaite m\u2019investir personnellement pour des investissements durables dans l\u2019industrie pharmaceutique suisse et encourager des initiatives visant \u00e0 r\u00e9soudre les d\u00e9fis et probl\u00e8mes mentionn\u00e9s plus haut. J\u2019entends coop\u00e9rer avec des d\u00e9cideurs importants pour mettre en place des relations solides entre l\u2019industrie, le monde universitaire et les autorit\u00e9s publiques. Je soutiendrai aussi la cr\u00e9ation d\u2019une future plaque tournante de donn\u00e9es de sant\u00e9 en Suisse et je m\u2019engagerai pour des mesures susceptibles de r\u00e9duire la charge administrative qui p\u00e8se sur la recherche clinique et l\u2019acc\u00e8s aux m\u00e9dicaments. Enfin, je suivrai avec attention les n\u00e9gociations sur un nouvel accord institutionnel avec l\u2019UE et je m\u2019engagerai pour un r\u00e9sultat positif, b\u00e9n\u00e9ficiant \u00e0 l\u2019industrie pharmaceutique suisse.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Quelles sont les forces et les chances de la Suisse en tant que place de recherche et d\u2019innovation? La Suisse a une longue tradition de performances de pointe dans l\u2019industrie pharmaceutique, avec de grands groupes internationaux comme Novartis, Roche et Nestl\u00e9, ainsi que de nombreuses entreprises de biotechnologie et de g\u00e9nie m\u00e9dical. Une autre grande [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2823,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[],"class_list":["post-12671","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) - Vice Chair Innovation Hub Committee - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) - Vice Chair Innovation Hub Committee\" \/>\n<meta property=\"og:description\" content=\"Quelles sont les forces et les chances de la Suisse en tant que place de recherche et d\u2019innovation? La Suisse a une longue tradition de performances de pointe dans l\u2019industrie pharmaceutique, avec de grands groupes internationaux comme Novartis, Roche et Nestl\u00e9, ainsi que de nombreuses entreprises de biotechnologie et de g\u00e9nie m\u00e9dical. Une autre grande [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T07:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T09:45:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) &#8211; Vice Chair Innovation Hub Committee\",\"datePublished\":\"2023-04-18T07:00:00+00:00\",\"dateModified\":\"2026-03-03T09:45:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/\"},\"wordCount\":734,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg\",\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/\",\"name\":\"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) - Vice Chair Innovation Hub Committee - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg\",\"datePublished\":\"2023-04-18T07:00:00+00:00\",\"dateModified\":\"2026-03-03T09:45:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) &#8211; Vice Chair Innovation Hub Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) - Vice Chair Innovation Hub Committee - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/","og_locale":"fr_FR","og_type":"article","og_title":"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) - Vice Chair Innovation Hub Committee","og_description":"Quelles sont les forces et les chances de la Suisse en tant que place de recherche et d\u2019innovation? La Suisse a une longue tradition de performances de pointe dans l\u2019industrie pharmaceutique, avec de grands groupes internationaux comme Novartis, Roche et Nestl\u00e9, ainsi que de nombreuses entreprises de biotechnologie et de g\u00e9nie m\u00e9dical. Une autre grande [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/","og_site_name":"Interpharma","article_published_time":"2023-04-18T07:00:00+00:00","article_modified_time":"2026-03-03T09:45:18+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg","type":"image\/jpeg"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) &#8211; Vice Chair Innovation Hub Committee","datePublished":"2023-04-18T07:00:00+00:00","dateModified":"2026-03-03T09:45:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/"},"wordCount":734,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg","inLanguage":"fr-FR","copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/","name":"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) - Vice Chair Innovation Hub Committee - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg","datePublished":"2023-04-18T07:00:00+00:00","dateModified":"2026-03-03T09:45:18+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/04\/896_Interpharma-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-fragen-an-pierre-morneau-general-manager-takeda-schweiz-takeda-pharma-ag-vice-chair-innovation-hub-committee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"3 questions \u00e0 Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) &#8211; Vice Chair Innovation Hub Committee"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=12671"}],"version-history":[{"count":1,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12671\/revisions"}],"predecessor-version":[{"id":12672,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12671\/revisions\/12672"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/2823"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=12671"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=12671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}